Symbols

AVIR

Atea·NASDAQ

--(--)

AVIR fundamentals

AVIR Q4 2025 Earnings

Atea (AVIR) released its earnings on Mar 5, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.57 (YoY -42.50%), missed estimates.

Revenue / YoY

EPS / YoY

-0.57

-42.50%

Report date

Mar 5, 2026

AVIR Earnings Call Summary for Q4,2025

HCV Clinical Milestones: Global Phase III enrollment complete (1,760+ patients); top-line results expected mid-2026 (C-BEYOND) and end-2026 (C-FORWARD).
HEV Expansion: AT-587, a first-in-class HEV treatment, entering first-in-human trials mid-2026, targeting a $750M+ market with no approved therapies.
Financial Strength: $301.8M cash runway through 2027; 2025 R&D investment (+22%) focused on HCV and HEV programs.
Commercial Readiness: 75-person sales force; Phase II data shows 50% prescriber interest in new 8-week regimen with no food effect.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Atea (AVIR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Atea (AVIR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Atea (AVIR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Atea (AVIR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown